Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-
Clinical Trials
Related News

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

First Posted Date
2023-07-18
Last Posted Date
2024-07-26
Lead Sponsor
Fate Therapeutics
Target Recruit Count
166
Registration Number
NCT05950334
Locations
🇺🇸

Karmanos Cancer Center, Detroit, Michigan, United States

🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

First Posted Date
2023-07-06
Last Posted Date
2023-07-06
Lead Sponsor
Fate Therapeutics
Registration Number
NCT05934097

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

First Posted Date
2023-06-12
Last Posted Date
2023-06-12
Lead Sponsor
Ruijin Hospital
Target Recruit Count
332
Registration Number
NCT05899621
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

First Posted Date
2023-05-08
Last Posted Date
2023-11-29
Lead Sponsor
University of Birmingham
Target Recruit Count
284
Registration Number
NCT05848765
Locations
🇬🇧

Cardiff and vale University LHB, Cardiff, United Kingdom

🇬🇧

Belfast Health & Social Care Trust, Belfast, United Kingdom

🇬🇧

NHS Grampian, Aberdeen, United Kingdom

and more 22 locations

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

First Posted Date
2023-02-03
Last Posted Date
2024-03-20
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT05711628

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

First Posted Date
2022-11-22
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
300
Registration Number
NCT05624554
Locations
🇺🇸

Highlands Oncology Group ( Site 5205), Springdale, Arkansas, United States

🇺🇸

Clermont Oncology Center ( Site 5224), Clermont, Florida, United States

🇺🇸

Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, United States

and more 94 locations

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

First Posted Date
2022-09-23
Last Posted Date
2024-12-20
Lead Sponsor
Vaishalee Kenkre
Target Recruit Count
42
Registration Number
NCT05551936
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 2 locations

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

First Posted Date
2022-08-19
Last Posted Date
2024-12-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
360
Registration Number
NCT05508867
Locations
🇨🇳

Sun Yat-sen University Cancer Center ( Site 0500), Guangzhou, Guangdong, China

🇺🇸

The University of Arizona Cancer Center - North Campus ( Site 2216), Tucson, Arizona, United States

🇺🇸

UCLA Hematology/Oncology - Santa Monica ( Site 2208), Los Angeles, California, United States

and more 102 locations

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

First Posted Date
2022-07-11
Last Posted Date
2024-06-28
Lead Sponsor
Rajshekhar Chakraborty, MD
Target Recruit Count
53
Registration Number
NCT05451771
Locations
🇺🇸

New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States

🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

First Posted Date
2022-05-12
Last Posted Date
2024-11-22
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
230
Registration Number
NCT05371093
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States

🇺🇸

UC Irvine Health, Orange, California, United States

and more 65 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy